# of pts | Clinical trial | Indications for GTX | Remarks/outcome | Reference(s) |
---|---|---|---|---|
27 | Prospective, phase II | Severe neutropenia and infections | Donor mobilization: 7.5 μg/kg G-CSF; resolution of infection in 92.6 % of patients; 81.5 % OS on day +30; early administration after a median infection period of 6 days | [41] |
49 | Prospective | Neutropenia and invasive bacterial or fungal infection | Donor mobilization with 5 μg/kg G-CSF + 50 mg PDN. Mixed cohort, including 10 adults; 72 % OS on day +28 and 52 % OS on day +100 | [42] |
13 | Prospective phase I/II | Neutropenia and severe infection | Donor mobilization with 5–10 μg/kg G-CSF; Collection through the bag method. 69 % OS on day +30 | [90] |
3 | Prospective | CGD and invasive aspergillosis | Donor’s mobilization with 450 μg G-CSF + 8 mg DXM; one patient died for ARDS, one was lost at follow-up and died 1 year after discharge, one is alive | [49] |
35 | Retrospective | Febrile neutropenia or defective granulocyte function | Donor mobilization with 480 μg G-CSF + 8 mg DXM; OS 77.1 and 65.7 %, respectively, on day +30 and +60; 82.4 % infection-related OS | [40] |
32 | Retrospective | Sepsis and neutropenia | Donor mobilization with single-dose lenograstim + DXM 8 mg; 59 % OS (8/32 pts died for the underlying infection and 8/32 pts for non-infectious causes) | [39] |
16 | Retrospective | Severe neutropenia and documented bacterial and/or fungal infections in HSCT recipients | Donor mobilization with 8Â mg DXM after 2007; unstimulated donors before 2007; 50Â % OS on day +30 | [37] |
10 | Retrospective | High risk febrile neutropenia with/without microbiologically documented severe infection | Donor mobilization with 5 μg/kg G-CSF + 8 mg DXM; Clinical response rate 62.9 %, 40 % infection-related mortality, 40 OS  % | [91] |
13 | Retrospective | Febrile neutropenia | Resolution of the documented infection in 9/12 (75Â %) pts; good early survival (12/14 courses of GTX, 86Â %); poor long-term survival (5/13 pts, 39Â %) | [47] |
13 | Retrospective | Severe infections and neutropenia | Donor mobilization with G-CSF 300 μg from day -3; complete or partial recovery in 6 and 3 of the 15 courses of GTX (40 and 20 % respectively) | [43] |
13 | Retrospective | Granulocyte dysfunction or severe neutropenia and acute life-threatening infections | Donor mobilization with 600 μg G-CSF + 8 mg DXM; complete or partial clinical response in 12/13 pts (92 %); 15 % infection-related mortality and 42 % OS | [38] |
3 | Retrospective | Secondary prophylaxis of invasive fungal infections during neutropenic episodes | Donor mobilization with G-CSF; concomitant combination antifungal therapy; no infection-related mortality | [39] |
3 | Prospective | Prophylaxis in HSC recipients with chronic infections | Donor mobilization with 480 μg G-CSF + 7.5 mg DXM; after transplant, no flares of the infections (active S. aureus liver abscesses, chronic pulmonary aspergillosis, soft tissue mucormycosis) | [50] |
20 | Prospective | Proven fungal or bacterial infection, unresponsive to anti-microbial therapy (n = 16). Poor control of fungal infection prior to allogeneic HSCT (n = 4) | In the curative group, infection was controlled in 11 out of 16 children. All patients treated pre-emptively survived the HSCT procedure | [24] |
10 | Prospective | CGD with severe infections | Resolution of infection in 9 out of 10 patients, despite the fact that 8 patients were alloimmunized and had poor recovery of transfused granulocytes | [65] |